Selecta Biosciences (SELB) Issues Earnings Results

Selecta Biosciences (NASDAQ:SELB) released its earnings results on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.08, MarketWatch Earnings reports.

Shares of Selecta Biosciences stock traded down $0.29 during trading hours on Friday, reaching $5.51. 347,760 shares of the company’s stock were exchanged, compared to its average volume of 238,999. Selecta Biosciences has a fifty-two week low of $4.74 and a fifty-two week high of $16.55. The company has a debt-to-equity ratio of 0.87, a current ratio of 4.96 and a quick ratio of 4.96. The company has a market cap of $120.49 million, a price-to-earnings ratio of -1.72 and a beta of 0.91.

A number of research firms have issued reports on SELB. UBS Group set a $6.00 target price on Selecta Biosciences and gave the stock a “hold” rating in a report on Friday. BidaskClub downgraded shares of Selecta Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Zacks Investment Research downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, August 29th. Mizuho restated a “buy” rating and set a $30.00 price objective on shares of Selecta Biosciences in a research note on Wednesday, October 17th. Finally, Stifel Nicolaus restated a “buy” rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $23.83.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Selecta Biosciences by 1.5% during the 3rd quarter. BlackRock Inc. now owns 897,480 shares of the company’s stock worth $13,956,000 after buying an additional 12,916 shares during the last quarter. Artal Group S.A. boosted its stake in shares of Selecta Biosciences by 12.3% during the 3rd quarter. Artal Group S.A. now owns 561,540 shares of the company’s stock worth $8,732,000 after buying an additional 61,540 shares during the last quarter. Wasatch Advisors Inc. boosted its stake in shares of Selecta Biosciences by 9.2% during the 2nd quarter. Wasatch Advisors Inc. now owns 235,625 shares of the company’s stock worth $3,122,000 after buying an additional 19,803 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Selecta Biosciences by 11.9% during the 2nd quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock worth $2,076,000 after buying an additional 16,615 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Selecta Biosciences during the 2nd quarter worth about $1,583,000. Institutional investors own 48.63% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/10/selecta-biosciences-selb-issues-earnings-results.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Featured Article: How to Invest in the Dividend Aristocrat Index

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply